Congress funds study to close HPV testing gap for men
H.R. 8939 — Closing the HPV Testing Gap Act · Filed by LaMonica McIver (D-NJ) · 20 cosponsors · Introduced May 20, 2026 · Referred to committee
Your members of Congress
Enter a ZIP to see where your representative and both senators stood on this bill.
Looked up on this device — your ZIP is never stored on our servers.
What it does
This bill directs the National Institutes of Health to study how to develop and test for HPV (human papillomavirus) in men, a gap that currently exists since no FDA-approved HPV diagnostic test for men is available. The study will examine noninvasive testing methods, assess feasibility across diverse populations, and recommend regulatory pathways for approval and equitable access, with a final report due within 30 months.
Why we flagged it
The bill is a straightforward research directive with no regulatory or commercial carve-outs. It funds NIH to study a documented public health gap and report findings to Congress—a standard evidence-gathering mechanism for policy development.
What the text implies
- Successful development of an HPV test for men could eventually lead to routine screening recommendations, creating ongoing demand for testing infrastructure and potentially affecting clinical laboratory capacity and reimbursement models.
- The study's focus on 'diverse populations' and 'underserved communities' may surface disparities in HPV prevalence and cancer risk among men, potentially informing future targeted public health interventions.
- Interagency coordination language (FDA, CDC, HRSA, National Academy of Medicine) suggests the bill anticipates regulatory and implementation challenges; delays or disagreement could slow test approval and deployment.
Who it affects
The bill addresses a documented public health gap by funding research into HPV testing for men, which could improve cancer prevention, reduce transmission to women, and promote gender equity in health screening. There are no apparent costs to ordinary citizens—only research investment and potential future public health gains.
Who stands to gain
- diagnostic test manufacturers (future)
- clinical laboratories
- research institutions conducting pilot studies
Named in the bill
National Institutes of Health (NIH), Food and Drug Administration (FDA), Centers for Disease Control and Prevention (CDC), Health Resources and Services Administration (HRSA), National Academy of Medicine, human papillomavirus (HPV)
Where it stands
20 cosponsors: 20 Democrats.
- May 20, 2026 — Introduced · Congress.gov: “Introduced in House”
- May 20, 2026 — Referred to House Committee on Energy and Commerce · Congress.gov: “Referred to the House Committee on Energy and Commerce”
Dates and quoted wording are Congress.gov's action record; the timeline shows status changes, not every procedural step.
How this was measured
Analysis — Quorum's AI read the full bill text on Jul 9, 2026; transparency and hidden-provision scores are compared against the median of 16,222 analysed bills.
Status and sponsors — Congress.gov's bill record — actions, committee referrals and cosponsors — loaded nightly. The timeline shows status changes, not every procedural action.
As of — page rendered 2026-10-20.
“Congress funds study to close HPV testing gap for men” QuorumCivic. https://share.quorumcivic.app/bill/119/hr8939 Report an error
The week in bills
One email, Sunday: what Congress passed, what it changed, and who paid.
One link arrives to confirm the address. It is used for this email and nothing else, and every issue carries an unsubscribe link.